Substituted azabicyclic moieties for the treatment of disease
    10.
    发明授权
    Substituted azabicyclic moieties for the treatment of disease 失效
    用于治疗疾病的取代的氮杂双环部分

    公开(公告)号:US06869946B2

    公开(公告)日:2005-03-22

    申请号:US10124145

    申请日:2002-04-17

    摘要: The invention provides compounds of Formula I: wherein m1 is 0 or 1; m2 is 1 or 2; R1 is —H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or phenyl; R2 is —H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or phenyl, provided that when m1 is 1 at least one of R1 and R2 is —H; or a pharmaceutically acceptable salt, pharmaceutical composition, a pure enantiomer or racemic mixture thereof. The invention also provides a method for treating a disease or condition in a mammal, wherein the α7 nicotinic acetylcholine receptor is implicated and for treating diseases where there is a sensory-gating deficit in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of Formula I. These compounds may be in the form of pharmaceutical salts or compositions, and may be in pure enantiomeric form or may be racemic mixtures.

    摘要翻译: 本发明提供式I化合物:其中m 1为0或1; m 2为1或2; R 1为-H,烷基,卤代烷基,取代的烷基,环烷基或苯基; R 2为-H, 烷基,卤代烷基,取代的烷基,环烷基或苯基,条件是当m 1为1时,R 1和R 2中的至少一个为-H; 或其药学上可接受的盐,药物组合物,纯对映体或外消旋混合物。 本发明还提供了一种治疗哺乳动物疾病或病症的方法,其中所述α7烟碱乙酰胆碱受体涉及并用于治疗哺乳动物感觉门控缺陷的疾病,包括向哺乳动物施用治疗有效量的 式I化合物。这些化合物可以是药物盐或组合物的形式,并且可以是纯对映体形式或可以是外消旋混合物。